NZ334035A - Use of endokine alpha antagonists to diagnose and treat TNF-related disorders - Google Patents
Use of endokine alpha antagonists to diagnose and treat TNF-related disordersInfo
- Publication number
- NZ334035A NZ334035A NZ334035A NZ33403596A NZ334035A NZ 334035 A NZ334035 A NZ 334035A NZ 334035 A NZ334035 A NZ 334035A NZ 33403596 A NZ33403596 A NZ 33403596A NZ 334035 A NZ334035 A NZ 334035A
- Authority
- NZ
- New Zealand
- Prior art keywords
- amino acid
- endokine alpha
- acid sequence
- cytokine
- seq
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 2
- 239000002299 complementary DNA Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108700026244 Open Reading Frames Proteins 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000012163 sequencing technique Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C07K14/5255—Lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ334035A NZ334035A (en) | 1996-08-16 | 1996-08-16 | Use of endokine alpha antagonists to diagnose and treat TNF-related disorders |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ334035A NZ334035A (en) | 1996-08-16 | 1996-08-16 | Use of endokine alpha antagonists to diagnose and treat TNF-related disorders |
| PCT/US1996/013282 WO1998007880A1 (en) | 1996-08-16 | 1996-08-16 | Human endokine alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ334035A true NZ334035A (en) | 2000-09-29 |
Family
ID=22255618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ334035A NZ334035A (en) | 1996-08-16 | 1996-08-16 | Use of endokine alpha antagonists to diagnose and treat TNF-related disorders |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP0961831B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2000516474A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20010102191A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE412740T1 (cg-RX-API-DMAC7.html) |
| AU (4) | AU731123B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2264200A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69637734D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0961831T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2316153T3 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ334035A (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998007880A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001009327A2 (en) * | 1999-07-28 | 2001-02-08 | Genentech, Inc. | Method of preventing the injury or death of retinal cells and treating ocular diseases |
| US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
| US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
| WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US6713061B1 (en) | 1996-03-12 | 2004-03-30 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
| US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
| US6406867B1 (en) | 1996-08-16 | 2002-06-18 | Human Genome Sciences, Inc. | Antibody to human endokine alpha and methods of use |
| US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| WO2001040464A1 (en) * | 1999-11-30 | 2001-06-07 | Genentech, Inc. | Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization |
| US6689607B2 (en) | 1997-10-21 | 2004-02-10 | Human Genome Sciences, Inc. | Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| US6503184B1 (en) | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| DE69840413D1 (de) * | 1997-11-18 | 2009-02-12 | Genentech Inc | Dna 19355 polypeptide, ein homolog des tumornekrosefaktors |
| JP2002537769A (ja) * | 1999-02-26 | 2002-11-12 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ヒトエンドカインαおよび使用方法 |
| DE60038740T2 (de) * | 1999-06-02 | 2009-07-02 | Genentech, Inc., South San Francisco | Stimulierung oder hemmung von angiogenese und herzvaskularisierung |
| EP1983055A1 (en) | 2000-04-12 | 2008-10-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2001096528A2 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| WO2002002641A1 (en) | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
| AU2001288301A1 (en) | 2000-08-18 | 2002-03-04 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
| ES2437992T3 (es) | 2001-05-25 | 2014-01-15 | Human Genome Sciences, Inc. | Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL |
| EP2261250B1 (en) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin fusion proteins |
| JP5905184B2 (ja) | 2005-10-13 | 2016-04-20 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． | 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物 |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| WO2007123765A2 (en) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| MX2011003039A (es) | 2008-09-26 | 2011-08-15 | Tocagen Inc | Vectores de terapia genica y citosina deaminasas. |
| CN103874707B (zh) | 2010-11-19 | 2017-04-19 | 卫材R&D管理有限公司 | 中和抗‑ccl20抗体 |
| NL2005893C2 (nl) | 2010-12-22 | 2012-06-25 | Vanderlande Ind Bv | Systeem en werkwijze voor het bufferen van bagagestukken. |
| EP2909324B1 (en) | 2012-10-25 | 2020-02-26 | Tocagen Inc. | Retroviral vector with mini-promoter cassette |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US599817A (en) * | 1898-03-01 | Cash-register | ||
| US4433092A (en) | 1981-03-09 | 1984-02-21 | Champion Spark Plug Company | Green ceramic of lead-free glass, conductive carbon, silicone resin and AlPO4, useful, after firing, as an electrical resistor |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3472793D1 (en) * | 1983-12-26 | 1988-08-25 | Asahi Chemical Ind | A novel physiologically active polypeptide |
| US5288852A (en) * | 1984-03-06 | 1994-02-22 | Dainippon Pharmaceutical Co., Ltd. | Human tumor necrosis factor polypeptides |
| DE3586772T2 (de) | 1984-07-24 | 1993-03-04 | Coselco Mimotopes Pty Ltd | Verfahren zur bestimmung von mimotopen. |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| WO1987001130A1 (en) | 1985-08-15 | 1987-02-26 | Stauffer Chemical Company | Tryptophan producing microorganism |
| ATE114673T1 (de) * | 1985-08-16 | 1994-12-15 | Univ Rockefeller | Modulator der anabolischen aktivität und seine verwendungen. |
| US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
| LU86128A1 (fr) | 1985-10-18 | 1987-06-02 | Vander Poorten Henri | Procede permettant l'impression ou le revetement de ceramique simultanement a son electroformage et conduisant en monocuisson a des produits decoratifs ou techniques |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| US5075236A (en) * | 1987-04-24 | 1991-12-24 | Teijin Limited | Method of detecting kawasaki disease using anti-tumor necrosis antibody |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| ATE169030T1 (de) | 1990-06-28 | 1998-08-15 | Hoechst Ag | Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung |
| US5480971A (en) | 1993-06-17 | 1996-01-02 | Houghten Pharmaceuticals, Inc. | Peralkylated oligopeptide mixtures |
| KR100507431B1 (ko) * | 1994-11-07 | 2005-12-21 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 종양괴사인자-γ |
| US5998171A (en) * | 1996-08-16 | 1999-12-07 | Human Genome Sciences, Inc. | Polynucleotides encoding human endokine alpha |
-
1996
- 1996-08-16 EP EP96928886A patent/EP0961831B1/en not_active Expired - Lifetime
- 1996-08-16 JP JP10510675A patent/JP2000516474A/ja not_active Withdrawn
- 1996-08-16 NZ NZ334035A patent/NZ334035A/xx not_active IP Right Cessation
- 1996-08-16 WO PCT/US1996/013282 patent/WO1998007880A1/en not_active Ceased
- 1996-08-16 AU AU68478/96A patent/AU731123B2/en not_active Ceased
- 1996-08-16 EP EP08018826A patent/EP2025682A3/en not_active Withdrawn
- 1996-08-16 AT AT96928886T patent/ATE412740T1/de active
- 1996-08-16 DE DE69637734T patent/DE69637734D1/de not_active Expired - Lifetime
- 1996-08-16 KR KR1020017010401A patent/KR20010102191A/ko not_active Ceased
- 1996-08-16 ES ES96928886T patent/ES2316153T3/es not_active Expired - Lifetime
- 1996-08-16 DK DK96928886T patent/DK0961831T3/da active
- 1996-08-16 CA CA002264200A patent/CA2264200A1/en not_active Abandoned
-
2001
- 2001-06-20 AU AU53937/01A patent/AU764278B2/en not_active Withdrawn - After Issue
-
2003
- 2003-10-28 AU AU2003257892A patent/AU2003257892A1/en not_active Abandoned
-
2007
- 2007-06-08 AU AU2007202630A patent/AU2007202630B8/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP0961831A4 (en) | 2002-06-12 |
| AU2007202630A1 (en) | 2007-06-28 |
| EP0961831B1 (en) | 2008-10-29 |
| DE69637734D1 (de) | 2008-12-11 |
| KR20010102191A (ko) | 2001-11-15 |
| DK0961831T3 (da) | 2009-01-12 |
| ES2316153T3 (es) | 2009-04-01 |
| CA2264200A1 (en) | 1998-02-26 |
| AU5393701A (en) | 2001-08-16 |
| AU764278B2 (en) | 2003-08-14 |
| AU731123B2 (en) | 2001-03-22 |
| AU2007202630B8 (en) | 2010-08-19 |
| AU6847896A (en) | 1998-03-06 |
| EP2025682A2 (en) | 2009-02-18 |
| WO1998007880A1 (en) | 1998-02-26 |
| AU2007202630B2 (en) | 2010-04-22 |
| ATE412740T1 (de) | 2008-11-15 |
| AU2003257892A1 (en) | 2003-11-20 |
| EP0961831A1 (en) | 1999-12-08 |
| JP2000516474A (ja) | 2000-12-12 |
| EP2025682A3 (en) | 2009-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ334035A (en) | Use of endokine alpha antagonists to diagnose and treat TNF-related disorders | |
| Cox | Endogenous opioid peptides: a guide to structures and terminology | |
| Wagener et al. | Primary structure of matrilin-3, a new member of a family of extracellular matrix proteins related to cartilage matrix protein (matrilin-1) and von Willebrand factor | |
| Pancer et al. | On the origin of Metazoan adhesion receptors: cloning of integrin alpha subunit from the sponge Geodia cydonium. | |
| Ouellette et al. | Purification and primary structure of murine cryptdin‐1, a Paneth cell defensin | |
| CA2343655A1 (en) | Interleukin 17-like receptor protein | |
| WO1994012638A3 (en) | Interleukin-3 (il-3) multiple mutation polypeptides | |
| DE10075019I2 (de) | Neue Proteine mit TNF-Hemmender Wirkung und ihre Herstellung. | |
| CA2266439A1 (en) | Neutrokine .alpha. | |
| AU7608898A (en) | Ntn-2 member of tnf ligand family | |
| EP1012292A1 (en) | Ntn-2 member of tnf ligand family | |
| DE951551T1 (de) | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie | |
| MX9703476A (es) | Factor derivado de neuronas sensoriales y motoras (smdf). | |
| RU95117238A (ru) | Нуклеиновая кислота, рекомбинантная плазмида, рекомбинантный вектор, белок, синтетический пептид, химерная молекула, иммуногенная композиция, антисыворотка или антитела | |
| KR970701776A (ko) | 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1) | |
| AU6250098A (en) | Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l) | |
| RU99107759A (ru) | Применение антагонистов лептина для лечения резистентности к инсулину при диабете ii типа | |
| CA2338186A1 (en) | Tumor necrosis factor-gamma | |
| AU2028497A (en) | Metabotropic gaba{b} receptors, receptor-specific ligands and their uses | |
| CA2378543A1 (en) | Modified human granulocyte-colony stimulating factor and process for producing same | |
| RU2002103159A (ru) | Модифицированный колониестимулирующий фактор гранулоцитов человека и способ его получения, днк, экспрессирующий вектор | |
| US6447996B1 (en) | Galanin receptors, nucleic acids, transformed cells and uses thereof | |
| KR940005798A (ko) | 지방세포화 억제 인자 유도체, 그의 제조방법 및 용도 | |
| CA2265500A1 (en) | Novel semaphorin gene: semaphorin y | |
| Wang et al. | The analgesic domain of IL-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |